Literature DB >> 9679738

Peritoneum and tissues of the female reproductive tract as physiological sources of CA-125.

A G Zeimet1, F A Offner, E Müller-Holzner, M Widschwendter, B Abendstein, L C Fuith, G Daxenbichler, C Marth.   

Abstract

The origin of physiological CA-125 serum levels, which in normally menstruating women were shown to depend on their actual menstrual cycle phase, has not yet been completely elucidated. It is furthermore conceivable that physiological CA-125 sources may contribute to serum elevations in the various pathologies associated with increased circulating CA-125. The present review deals with menstrual cycle-dependent expression of CA-125 in normal tissues of the female reproductive tract in relation to the actual circulating CA-125 levels together with in vivo data concerning the inductive effect of medroxyprogesterone acetate on circulating CA-125 studied in 24 postmenopausal women. Furthermore, in vitro results on constitutive, steroid hormone- and cytokine-modulated CA-125 shedding from human peritoneal mesothelial and ovarian surface epithelial cells are summarized.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9679738     DOI: 10.1159/000030018

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  9 in total

Review 1.  Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells.

Authors:  S Bafna; S Kaur; S K Batra
Journal:  Oncogene       Date:  2010-03-29       Impact factor: 9.867

2.  Transmembrane mucins as novel therapeutic targets.

Authors:  Pamela E Constantinou; Brian P Danysh; Neeraja Dharmaraj; Daniel D Carson
Journal:  Expert Rev Endocrinol Metab       Date:  2011-11

3.  Mucin 16 is a functional selectin ligand on pancreatic cancer cells.

Authors:  Shih-Hsun Chen; Matthew R Dallas; Eric M Balzer; Konstantinos Konstantopoulos
Journal:  FASEB J       Date:  2011-12-09       Impact factor: 5.191

4.  Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery.

Authors:  Nathalie Scholler; Barbara Garvik; Martha Hayden-Ledbetter; Toni Kline; Nicole Urban
Journal:  Cancer Lett       Date:  2006-05-04       Impact factor: 8.679

5.  Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes.

Authors:  Jennifer A Belisle; Sachi Horibata; Gubbels A A Jennifer; Sarah Petrie; Arvinder Kapur; Sabine André; Hans-Joachim Gabius; Claudine Rancourt; Joseph Connor; James C Paulson; Manish S Patankar
Journal:  Mol Cancer       Date:  2010-05-24       Impact factor: 27.401

6.  Serum CA 125 expression as a tumor marker for diagnosis and monitoring the clinical course of epithelioid sarcoma.

Authors:  Makiko Hoshino; Hiroyuki Kawashima; Akira Ogose; Naoko Kudo; Takashi Ariizumi; Tetsuo Hotta; Hajime Umezu; Hiroshi Hatano; Tetsuro Morita; Jyun Nishio; Hiroshi Iwasaki; Naoto Endo
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-16       Impact factor: 4.553

7.  MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse.

Authors:  Ying Wang; Dong-Joo Cheon; Zhen Lu; Sheena L Cunningham; Chun-Ming Chen; Robert Z Luo; Deyin Xing; Sandra Orsulic; Robert C Bast; Richard R Behringer
Journal:  Differentiation       Date:  2008-07-02       Impact factor: 3.880

8.  Clinical characteristics of genital chlamydia infection in pelvic inflammatory disease.

Authors:  Sung Taek Park; Suk Woo Lee; Min Jeong Kim; Young Mo Kang; Hye Min Moon; Chae Chun Rhim
Journal:  BMC Womens Health       Date:  2017-01-13       Impact factor: 2.809

9.  Clinical characteristics, treatment status and complications in women with tube ovarian abscess and endometriosis: a retrospective study.

Authors:  Hui Li; Yan Zhao; Xiao-Hong Chang; Yue Wang; Hong-Lan Zhu
Journal:  BMC Womens Health       Date:  2021-03-18       Impact factor: 2.809

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.